Cytek BiosciencesvsJohnson & Johnson

CTKB and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CTKB

Cytek Biosciences, Inc.

$5.70

Value $733M

+1.24%
CTKB's page

Cytek Biosciences (CTKB) has a market value of $733M and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, CTKB moved +3.6% and JNJ +45.4%. Dividend yield: CTKB none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CTKB$733M

    JNJ$672B

    JNJ is 917 times CTKB

  • Revenue, 12 months

    CTKB$208M

    JNJ$99.3B

    JNJ is 478 times CTKB

  • Net income, 12 months

    CTKB-$81M

    JNJ$16.1B

  • Operating margin

    CTKB-21.1%

    JNJ–

  • ROIC

    CTKB-10.3%

    JNJ12.4%

    22.6 points apart

  • P/E

    CTKB–

    JNJ41.7

  • Dividend yield

    CTKB0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    CTKB-75.2%

    JNJ+97.0%

    172.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CTKB-75.2%

JNJ+96.9%

010020020222023202420252026
Returns by period
PeriodCTKBWith dividendsJNJWith dividends
1 year since November 14, 2025+3.6%Price +3.6%+45.4%Price +42.2%
3 years since November 17, 2023-4.7%-1.6% a yearPrice -4.7%+102.6%+26.5% a yearPrice +86.1%
5 years since November 16, 2021-75.2%-24.3% a yearPrice -75.2%+97.0%+14.5% a yearPrice +71.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CTKBCytek BiosciencesJNJJohnson & Johnson

Valuation

CTKBJNJ
Valuation
Price$5.70$278.70
Market value$733M$672B
Enterprise value (EV)$666M$699B
P/E–41.7
P/E, 5-year median–21.9
P/B2.38.2
EV/EBIT–39.4
Free cash flow yield–3.1%

Results and growth

CTKBJNJ
Results and growth
Revenue, 12 months$208M$99.3B
Net income, 12 months-$81M$16.1B
Free cash flow, 12 months-$13M$20.6B
Earnings per share, 12 months-$0.63$6.59
Revenue growth, year on year0.5%6.1%
Revenue growth a year, past+16.8%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CTKBJNJ
Margins and returns on capital
Gross margin54.8%67.6%
Operating margin-21.1%–
Net margin-39.1%16.2%
ROIC-10.3%12.4%
ROE-24.0%19.7%

Balance sheet

CTKBJNJ
Balance sheet
Cash$67M$17.2B
Total debt$16M$44.7B
Net debt / EBITDA–1.1
Interest cover-562.6×18.0×

Dividends and buybacks

CTKBJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield2.1%0.9%
Shareholder yield2.1%2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CTKB or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Cytek Biosciences or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 916.6 times Cytek Biosciences ($733M), at today's prices.

How did CTKB and JNJ stock do over the last 5 years?

Since November 16, 2021, CTKB's price moved -75.2% and JNJ's +71.3%. With dividends: CTKB -75.2% (-24.3% a year), JNJ +97.0% (+14.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, CTKB or JNJ?

The dividend yield at today's price is none for Cytek Biosciences and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Cytek Biosciences or Johnson & Johnson?

Over the last twelve months, the net margin was -39.1% for Cytek Biosciences and 16.2% for Johnson & Johnson, and the operating margin -21.1% and –. Revenue was $208M and $99.3B.

Which is the better investment, Cytek Biosciences or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.